Bright Minds Biosciences (DRUG) Price & Analysis

Compare

66 Followers

DRUG Stock Chart & Stats

C$101.45

C$0.00(0.00%)

At close: Jan 07 4:00 PM EST

C$101.45

C$0.00(0.00%)

Day’s Range― - ―

52-Week RangeC$33.01 - C$99.95

Previous CloseN/A

Volume70.00

Average Volume (3M)451.00

Market Cap

C$515.83M

Enterprise ValueC$204.27M

Total Cash (Recent Filing)C$51.39M

Total Debt (Recent Filing)C$141.03K

Price to Earnings (P/E)―

Beta25.19

Next Earnings

Dec 18, 2025

EPS Estimate

-0.79

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.74

Shares Outstanding7,084,639

10 Day Avg. Volume620

30 Day Avg. Volume451

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)1.14

Price to Sales (P/S)0.00

P/FCF Ratio-3.42

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$111.23

Price Target Upside9.64% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical ExpansionBright Minds broadens its 5-HT2C clinical footprint with expansion into Prader-Willi syndrome (PWS), marking a significant strategic step in extending its serotonergic platform beyond seizure disorders into metabolic and neurobehavioral disease.

Pipeline AdvancementThe introduction of BMB-105 as a next-generation 5-HT2C agonist and dedicated PWS candidate complements ongoing clinical work with BMB-101, further extending Bright Minds' leadership in 5-HT2C agonism.

Strategic Drug DesignBright Minds highlighted BMB-202, a highly promising A agonist in investigational new drug studies for depression, reflecting a broader strategy to apply serotonergic drug design across neurology and psychiatry, thus broadening the pipeline beyond rare conditions.

Bears Say

Bright Minds Biosciences News

Bright Minds price target raised to $82 from $75 at Baird

Baird raised the firm’s price target on Bright Minds (DRUG) to $82 from $75 and keeps an Outperform...

28d ago

DRUG

Psychedelic: Compass Pathways, GH Research report Q3 earnings

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

28d ago

PBM

ATAI

Bright Minds Biosciences Strengthens Advisory Board with PWS Experts

Bright Minds Biosciences ( ($TSE:DRUG) ) just unveiled an update. Bright Minds Biosciences has expanded its Scientific Advisory...

17d ago

DRUG

Bright Minds Biosciences: Strategic Advancements in Serotonergic Therapies and Expansion into Prader-Willi Syndrome

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Bright Minds Biosciences,...

24d ago

DRUG

Bright Minds Biosciences Launches New Prader-Willi Syndrome Program

An update from Bright Minds Biosciences ( ($TSE:DRUG) ) is now available. Bright Minds Biosciences has announced the...

27d ago

DRUG

Bright Minds Biosciences to Present at Key Healthcare Conferences and Grants Equity Incentives

Bright Minds Biosciences ( ($TSE:DRUG) ) just unveiled an announcement. Bright Minds Biosciences announced its participation in upcoming...

27d ago

DRUG

Bright Minds Biosciences Advances Epilepsy Treatment with BMB-101 Study

Bright Minds Biosciences Inc. (($TSE:DRUG)) announced an update on their ongoing clinical study. Bright Minds Biosciences Inc. is...

1M ago

DRUG

Bright Minds Biosciences’ Promising Pipeline and Strategic Expansion Justify Buy Rating

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Bright Minds Biosciences, retaining the price target...

3M ago

DRUG

Psychedelic: Cybin completes enrollment in CYB004 Phase 2 study

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

3M ago

CYBN

DRUG

Bright Minds initiated with a Buy at BTIG

BTIG initiated coverage of Bright Minds (DRUG) with a Buy rating and $72 price target The company is...

3M ago

DRUG

Bright Minds Biosciences Launches $100 Million At-The-Market Offering

Bright Minds Biosciences ( ($TSE:DRUG) ) has provided an update. Bright Minds Biosciences announced an at-the-market equity offering...

3M ago

DRUG

Psychedelic: Bright Minds reports preclinical BMB-201 results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

3M ago

CMPS

CYBN

Bright Minds says BMB-201 outperforms sumatriptan in preclinical model

Bright Minds (DRUG) Biosciences announced preclinical results for its investigational compound BMB-201, in a validated isosorbide dinitrate rat...

3M ago

DRUG

Bright Minds Biosciences: Advancing Breakthrough Epilepsy Treatment with BMB-101 and Strong Financial Position

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Bright Minds Biosciences, retaining the price target...

4M ago

DRUG

DRUG FAQ

What was Bright Minds Biosciences’s price range in the past 12 months?

Bright Minds Biosciences lowest stock price was C$33.01 and its highest was C$99.95 in the past 12 months.

What is Bright Minds Biosciences’s market cap?

Bright Minds Biosciences’s market cap is C$515.83M.

When is Bright Minds Biosciences’s upcoming earnings report date?

Bright Minds Biosciences’s upcoming earnings report date is Dec 18, 2025 which is in 13 days.

How were Bright Minds Biosciences’s earnings last quarter?

Bright Minds Biosciences released its earnings results on Aug 14, 2025. The company reported -C$0.74 earnings per share for the quarter, beating the consensus estimate of -C$0.794 by C$0.054.

Is Bright Minds Biosciences overvalued?

According to Wall Street analysts Bright Minds Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bright Minds Biosciences pay dividends?

Bright Minds Biosciences does not currently pay dividends.

What is Bright Minds Biosciences’s EPS estimate?

Bright Minds Biosciences’s EPS estimate is -0.79.

How many shares outstanding does Bright Minds Biosciences have?

Bright Minds Biosciences has 7,084,639 shares outstanding.

What happened to Bright Minds Biosciences’s price movement after its last earnings report?

Bright Minds Biosciences reported an EPS of -C$0.74 in its last earnings report, beating expectations of -C$0.794. Following the earnings report the stock price went up 8.324%.

Which hedge fund is a major shareholder of Bright Minds Biosciences?

Currently, no hedge funds are holding shares in TSE:DRUG

Bright Minds Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-30.79%

Trailing 12-Months

Asset Growth

736.23%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bright Minds Biosciences

Bright Minds Biosciences (DRUG) is a biotechnology company focused on developing novel psychedelic and serotonergic compounds for the treatment of neuropsychiatric disorders, epilepsy, and other central nervous system (CNS) related conditions. Leveraging cutting-edge science and research, the company's core mission is to address unmet medical needs in mental health through innovation and advanced drug development.

Bright Minds Biosciences (DRUG) Earnings & Revenues

Historic Earnings Reports

DRUG Stock 12 Month Forecast

Average Price Target

C$111.23

▲(9.64% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"35":"C$35","56":"C$56","77":"C$77","98":"C$98","119":"C$119"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":118.67745815,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$118.68</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":111.23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$111.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100.52678808,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$100.53</span>\n  </div></div>","useHTML":true}}],"tickPositions":[35,56,77,98,119],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.07,80.27057370384615,83.4711474076923,86.67172111153846,89.8722948153846,93.07286851923077,96.27344222307693,99.47401592692307,102.67458963076923,105.8751633346154,109.07573703846154,112.2763107423077,115.47688444615386,{"y":118.67745815,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.07,79.69769230769231,82.3253846153846,84.95307692307692,87.58076923076922,90.20846153846153,92.83615384615385,95.46384615384616,98.09153846153846,100.71923076923076,103.34692307692308,105.97461538461539,108.6023076923077,{"y":111.23,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.07,78.87436831384615,80.6787366276923,82.48310494153846,84.28747325538461,86.09184156923077,87.89620988307692,89.70057819692308,91.50494651076923,93.30931482461538,95.11368313846154,96.9180514523077,98.72241976615385,{"y":100.52678808,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":67.15,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":67.15,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.59,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.98,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.11,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.03,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.99,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >